In vitroactivity of ceftazidime/avibactam against clinical isolates of ESBL-producingEnterobacteriaceaein Italy
| Autor: | Silvia Tonolo, Valentina Viaggi, Luigi Principe, Beatrice Pini, Francesco Luzzaro |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.drug_class Klebsiella pneumoniae Avibactam 030106 microbiology Antibiotics Cephalosporin Ceftazidime Context (language use) Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine polycyclic compounds medicine Pharmacology (medical) Pharmacology biology business.industry biochemical phenomena metabolism and nutrition bacterial infections and mycoses Ceftazidime/avibactam biology.organism_classification Enterobacteriaceae Infectious Diseases Oncology chemistry 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 31:195-201 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1080/1120009x.2019.1620406 |
| Popis: | Resistance to carbapenems in Enterobacteriaceae is a serious concern for public health. Alternative treatment options involving carbapenem-sparing regimen for patients with serious infections caused by multidrug-resistant Enterobacteriaceae are urgently needed. Ceftazidime/avibactam (CZA) is a new combination of a third generation cephalosporin and a non-β-lactam β-lactamase inhibitor, in which avibactam is capable to expand the ceftazidime activity also against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. To date, no data exist regarding the activity of CZA against strains isolated in the Italian context, which is known as endemic for ESBL producers. The aim of this study was to evaluate the in vitro activity of CZA, in comparison to ceftazidime (CAZ), against 90 ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, collected from blood and urine samples at our Institute. Thus, avibactam has been able to restore the activity of CAZ in all cases, suggesting the potential use of CZA as a carbapenem-sparing model, especially when limited therapeutic options exist. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|